Autolus Therapeutics (AUTL) Operating Income (2018 - 2025)
Historic Operating Income for Autolus Therapeutics (AUTL) over the last 8 years, with Q3 2025 value amounting to -$71.6 million.
- Autolus Therapeutics' Operating Income fell 551.74% to -$71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$273.9 million, marking a year-over-year decrease of 2518.31%. This contributed to the annual value of -$241.4 million for FY2024, which is 3434.87% down from last year.
- Latest data reveals that Autolus Therapeutics reported Operating Income of -$71.6 million as of Q3 2025, which was down 551.74% from -$61.2 million recorded in Q2 2025.
- In the past 5 years, Autolus Therapeutics' Operating Income ranged from a high of -$40355.0 in Q3 2021 and a low of -$75.9 million during Q4 2024
- Its 5-year average for Operating Income is -$44.4 million, with a median of -$39.9 million in 2021.
- Its Operating Income has fluctuated over the past 5 years, first soared by 9990.55% in 2021, then tumbled by 9244615.29% in 2022.
- Autolus Therapeutics' Operating Income (Quarter) stood at -$23.1 million in 2021, then surged by 49.57% to -$11.6 million in 2022, then plummeted by 357.26% to -$53.3 million in 2023, then plummeted by 42.41% to -$75.9 million in 2024, then grew by 5.59% to -$71.6 million in 2025.
- Its Operating Income was -$71.6 million in Q3 2025, compared to -$61.2 million in Q2 2025 and -$65.2 million in Q1 2025.